Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy
ACS Chemical Biology · 21.08.2026 · 21 (8) · 1883-1890
DOI: 10.1021/acschembio.6c00253 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 27.07.2026. Verfasst von Riccardo Muzzioli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas77054, United States. Hauptthemen laut MEDLINE: Phthalazines, Radiopharmaceuticals, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Energy, University of Texas MD Anderson Cancer Center, NCI NIH HHS.
Abstract (Originalsprache)
Talazoparib (TZ) is a potent poly(ADP-ribose) polymerase 1/2 (PARP1/2) inhibitor that uniquely traps PARP complexes at sites of single-strand DNA damage thereby offering opportunities for targeted radioligand therapy. Radiolabeled halogenated TZ derivatives were synthesized using boronic ester precursors to enable incorporation of diagnostic and therapeutic radionuclides: 18F for PET imaging, 77Br for Auger electron radiotherapy, and 211At for targeted alpha radiotherapy. Copper-mediated radio-halogenation afforded racemic 18F-TZ, 77Br-TZ, and 211At-TZ in sufficient radiochemical yields (4.3 ± 2.6%, n = 33; 29.0 ± 12.0%, n = 4; 3.6 ± 3.8%, n = 9, respectively), ∼99% radiochemical purity and proven stability under formulation conditions. Molecular dynamics simulations of halo-TZ derivatives predicted an inverse relationship between halogen size and PARP1 binding affinity. Indeed, cell uptake of radio-halogenated TZ analogues indicated selective uptake in a panel of cell types that correlated with PARP1 levels but was inversely related to the atomic radii of the halogen series. Despite modest specific activity and specific uptake, 77Br-TZ showed significant cytotoxicity. Further investigation of 18F-TZ with 77Br-TZ as a radiotheranostic pair will be facilitated by the synthetic schemes herein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas77054, United States.
- Cyclotron Institute, Texas A&M University, College Station, Texas77843, United States.
- Chemistry Department, Texas A&M University, College Station, Texas77843, United States.
- Department of Chemistry, The University of Alabama at Birmingham, Birmingham, Alabama35294-1240, United States.
ORCID-Profile: Riccardo Muzzioli, Federica Pisaneschi, Seth T Gammon, Evgeny Tereshatov, Jonathan D Burns, David Piwnica-Worms
Förderung
- U.S. Department of Energy
- University of Texas MD Anderson Cancer Center
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Muzzioli, R., Pisaneschi, F., Gammon, S. T., Sutton, M. N., Napoli, A., Puglielli, R. B., McIntosh, L., Tereshatov, E., Tabacaru, G., Schultz, S., McCann, L., Burns, J. D., Yennello, S., & Piwnica-Worms, D. (2026). Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy. ACS Chemical Biology, 21(8), 1883-1890. https://doi.org/10.1021/acschembio.6c00253
Vancouver
Muzzioli R, Pisaneschi F, Gammon ST, Sutton MN, Napoli A, Puglielli RB, et al. Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy. ACS Chemical Biology. 2026;21(8):1883-1890. doi:10.1021/acschembio.6c00253
BibTeX
@article{Muzzioli2026,
author = {Muzzioli, Riccardo and Pisaneschi, Federica and Gammon, Seth T and Sutton, Margie N and Napoli, Arianna and Puglielli, Raffaele Bellini and McIntosh, Lauren and Tereshatov, Evgeny and Tabacaru, Gabriel and Schultz, Steven and McCann, Laura and Burns, Jonathan D and Yennello, Sherry and Piwnica-Worms, David},
title = {Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy},
journal = {ACS Chemical Biology},
year = {2026},
volume = {21},
number = {8},
pages = {1883--1890},
doi = {10.1021/acschembio.6c00253}
}
EUVIMED